No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
10% nifedipine cream |
Nifedipine |
D00437 |
[4] CACNA1C, CACNA1D, CACNA1F, CACNA1S |
[34] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[1] 50 |
2 |
3 mpdn pulse + pdn |
- |
- |
- |
- |
[1] 50 |
3 |
3 mpdn pulse + pdn + csa |
- |
- |
- |
- |
[1] 50 |
4 |
3 mpdn pulse + pdn + mtx |
- |
- |
- |
- |
[1] 50 |
5 |
44/154/85-c |
- |
- |
- |
- |
[1] 50 |
6 |
44/196/81-c |
- |
- |
- |
- |
[1] 50 |
7 |
5% sildenafil cream |
Sildenafil |
D02229, D08514 |
[1] PDE5A |
[3] Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
[1] 50 |
8 |
56/104/75-c |
- |
- |
- |
- |
[1] 50 |
9 |
Abatacept |
Abatacept |
D03203 |
[2] CD80, CD86 |
[12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
10 |
Abatacept subcutaneous |
Abatacept |
D03203 |
[2] CD80, CD86 |
[12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
[1] 50 |
11 |
Acthar |
Corticotropin |
D00146 |
[1] MC2R |
[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[6] 2, 13, 46, 49, 50, 222 |
12 |
Adrenocorticotropic hormone |
Corticotropin |
D00146 |
[1] MC2R |
[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[3] 13, 50, 84 |
13 |
Adrenocorticotropic hormone gel |
Corticotropin |
D00146 |
[1] MC2R |
[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 50 |
14 |
Ajulemic acid |
Ajulemic acid |
D11312 |
[1] CNR2 |
[1] Neuroactive ligand-receptor interaction |
[3] 50, 51, 299 |
15 |
Alendronate |
Alendronic acid |
D00939, D07119 |
[1] FDPS |
[4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
[7] 19, 41, 46, 50, 271, 274, 299 |
16 |
Alendronate versus alfacalcidol (1-alpha oh vitamin d) |
Alfacalcidol |
D01518 |
[1] VDR |
[4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
[3] 41, 46, 50 |
17 |
Alfacalcidol |
Alfacalcidol |
D01518 |
[1] VDR |
[4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
[6] 41, 46, 49, 50, 96, 235 |
18 |
Anakinra |
Anakinra |
D02934 |
[2] IL1R1, IL1R2 |
[15] Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
[15] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 84, 86, 106, 107, 299 |
19 |
Anti-pandemic h1n1 influenza vaccine |
- |
- |
- |
- |
[5] 46, 49, 50, 51, 53 |
20 |
Apremilast |
Apremilast |
D08860 |
[4] PDE4A, PDE4B, PDE4C, PDE4D |
[5] Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
[5] 46, 50, 56, 97, 271 |
21 |
Apremilast 30mg |
Apremilast |
D08860 |
[4] PDE4A, PDE4B, PDE4C, PDE4D |
[5] Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
[1] 50 |
22 |
Baf312 |
- |
- |
- |
- |
[2] 13, 50 |
23 |
Baf312 0.25 mg |
- |
- |
- |
- |
[1] 50 |
24 |
Baf312 0.25 mg tablet |
- |
- |
- |
- |
[1] 50 |
25 |
Baf312 0.50 mg |
- |
- |
- |
- |
[1] 50 |
26 |
Baf312 1 mg tablet |
- |
- |
- |
- |
[2] 13, 50 |
27 |
Baf312 1mg |
- |
- |
- |
- |
[1] 50 |
28 |
Baf312 2mg |
- |
- |
- |
- |
[1] 50 |
29 |
Baf312 4mg tablet |
- |
- |
- |
- |
[1] 50 |
30 |
Baf312 5 mg tablet |
- |
- |
- |
- |
[1] 50 |
31 |
Baf312 hemifumarate |
- |
- |
- |
- |
[2] 13, 50 |
32 |
Baf312x |
- |
- |
- |
- |
[1] 50 |
33 |
Baricitinib |
Baricitinib |
D10308 |
[2] JAK1, JAK2 |
[32] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
34 |
Basiliximab |
Basiliximab |
D03058 |
[1] IL2RA |
[11] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[6] 2, 50, 65, 97, 222, 228 |
35 |
Calcineurin inhibitors |
- |
- |
- |
- |
[1] 50 |
36 |
Ciclosporin |
Ciclosporin |
D00184 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[13] 26, 46, 49, 50, 53, 55, 60, 61, 97, 222, 226, 228, 269 |
37 |
Creapure |
- |
- |
- |
- |
[1] 50 |
38 |
Creatine |
Creatine |
- |
- |
- |
[12] 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
39 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[43] 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
40 |
Cyclosporine |
Ciclosporin |
D00184 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[33] 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
41 |
Denosumab |
Denosumab |
D03684 |
[1] TNFSF11 |
[7] Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis |
[7] 46, 50, 93, 95, 96, 274, 299 |
42 |
Etanercept |
Etanercept |
D00742 |
[2] LTA, TNF |
[61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[14] 15, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
43 |
Gamma globulin |
- |
- |
- |
- |
[2] 15, 50 |
44 |
Gb-0998 |
- |
- |
- |
- |
[1] 50 |
45 |
Gevokizumab |
Gevokizumab |
D09911 |
[1] IL1B |
[40] AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Prion diseases, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection |
[4] 41, 50, 56, 269 |
46 |
Glucose tablet |
- |
- |
- |
- |
[1] 50 |
47 |
Grapefruit |
Grapefruit |
- |
- |
- |
[5] 6, 46, 50, 83, 97 |
48 |
H.p. acthar gel |
- |
- |
- |
- |
[5] 46, 49, 50, 84, 222 |
49 |
H5g1.1-mab |
- |
- |
- |
- |
[1] 50 |
50 |
Hbvaxpro |
- |
- |
- |
- |
[2] 46, 50 |
51 |
Human immunoglobulin g |
Immune globulin human |
- |
- |
- |
[3] 14, 50, 63 |
52 |
Human normal immunoglobulin |
Immune globulin human |
- |
- |
- |
[8] 11, 13, 14, 43, 45, 50, 63, 65 |
53 |
Human normal immunoglobulin (ivig) |
Immune globulin human |
- |
- |
- |
[2] 50, 65 |
54 |
Ifn-k |
- |
- |
- |
- |
[2] 49, 50 |
55 |
Ifn-kinoid |
- |
- |
- |
- |
[2] 49, 50 |
56 |
Ifn-kinoid drug substance |
- |
- |
- |
- |
[2] 49, 50 |
57 |
Ifna-kinoid |
- |
- |
- |
- |
[1] 50 |
58 |
Ig vena |
- |
- |
- |
- |
[2] 50, 63 |
59 |
Ig vena (10g/200ml) |
- |
- |
- |
- |
[1] 50 |
60 |
Immunoglobulin (hizentra) |
- |
- |
- |
- |
[1] 50 |
61 |
Immunoglobulin g |
- |
- |
- |
- |
[7] 11, 13, 14, 49, 50, 63, 65 |
62 |
Immunosuppressive agents |
- |
- |
- |
- |
[2] 50, 66 |
63 |
Imo-8400 |
- |
- |
- |
- |
[1] 50 |
64 |
Imo-8400 dose group 1 |
- |
- |
- |
- |
[1] 50 |
65 |
Imo-8400 dose group 2 |
- |
- |
- |
- |
[1] 50 |
66 |
Impact |
Topramezone |
- |
- |
- |
[7] 6, 13, 46, 50, 96, 97, 299 |
67 |
Infliximab |
Infliximab |
D02598 |
[1] TNF |
[61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[22] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 95, 96, 97, 98, 162, 164, 269, 271 |
68 |
Influvac |
- |
- |
- |
- |
[3] 46, 49, 50 |
69 |
Ivig |
Immune globulin human |
- |
- |
- |
[12] 11, 13, 14, 17, 18, 50, 51, 63, 65, 85, 164, 296 |
70 |
Jbt-101 |
- |
- |
- |
- |
[4] 49, 50, 51, 299 |
71 |
Kzr-616 |
- |
- |
- |
- |
[3] 49, 50, 61 |
72 |
L0133 |
- |
- |
- |
- |
[1] 50 |
73 |
Lenabasum |
- |
- |
- |
- |
[3] 50, 51, 299 |
74 |
Lenabasum 20 mg |
- |
- |
- |
- |
[3] 50, 51, 299 |
75 |
Lenabasum 5 mg |
- |
- |
- |
- |
[3] 50, 51, 299 |
76 |
Lipid-lowering agents (artovastatin) |
- |
- |
- |
- |
[1] 50 |
77 |
Ly3009104 |
- |
- |
- |
- |
[4] 46, 49, 50, 325 |
78 |
Mabthera |
- |
- |
- |
- |
[15] 11, 13, 35, 46, 50, 51, 53, 61, 63, 64, 65, 83, 162, 222, 271 |
79 |
Medi-545 |
- |
- |
- |
- |
[2] 49, 50 |
80 |
Medi7734 |
- |
- |
- |
- |
[1] 50 |
81 |
Methimazole |
Methimazole |
D00401 |
[1] TPO |
[4] Autoimmune thyroid disease, Metabolic pathways, Thyroid hormone synthesis, Tyrosine metabolism |
[1] 50 |
82 |
Methotrexat |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[3] 13, 46, 50 |
83 |
Methotrexat lachema 2,5mg |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[1] 50 |
84 |
Methotrexat lachema 2,5mg tbl. |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[1] 50 |
85 |
Methotrexat lachema 5 inj. sol |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[1] 50 |
86 |
Methotrexate |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[33] 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
87 |
Methotrexate lachema 5inj. sol |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[1] 50 |
88 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[36] 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
89 |
Methylprednisoloni natrii succinas |
- |
- |
- |
- |
[1] 50 |
90 |
Nifedipine |
Nifedipine |
D00437 |
[4] CACNA1C, CACNA1D, CACNA1F, CACNA1S |
[34] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[2] 50, 81 |
91 |
Nivolumab |
Nivolumab |
D10316 |
[1] PDCD1 |
[3] Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway |
[10] 13, 26, 41, 46, 49, 50, 51, 53, 96, 97 |
92 |
Octagam 10% |
- |
- |
- |
- |
[3] 50, 63, 65 |
93 |
Octanorm |
- |
- |
- |
- |
[2] 50, 65 |
94 |
Octanorm 16.5% |
- |
- |
- |
- |
[2] 50, 65 |
95 |
Orencia |
Abatacept |
D03203 |
[2] CD80, CD86 |
[12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
[9] 46, 50, 51, 53, 65, 84, 96, 97, 271 |
96 |
Pf-06823859 |
- |
- |
- |
- |
[1] 50 |
97 |
Pirfenidone |
Pirfenidone |
D01583 |
[6] CCL2, IL10, IL1A, IL1B, IL6, TNF |
[80] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[10] 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
98 |
Placebo |
- |
- |
- |
- |
[20] 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
99 |
Pneumovax 23 |
- |
- |
- |
- |
[2] 46, 50 |
100 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[38] 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
101 |
Prednison 5, 20 léciva por. tablet nob |
- |
- |
- |
- |
[1] 50 |
102 |
Prednison 5, 20 léciva por. tablet nob. |
- |
- |
- |
- |
[1] 50 |
103 |
Prednisone |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[43] 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
104 |
Resunab, ajulemic acid, anabasum |
Ajulemic acid |
D11312 |
[1] CNR2 |
[1] Neuroactive ligand-receptor interaction |
[3] 50, 51, 299 |
105 |
Rituximab |
Rituximab |
D02994 |
[1] MS4A1 |
[1] Hematopoietic cell lineage |
[42] 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
106 |
S78989 |
- |
- |
- |
- |
[3] 41, 50, 56 |
107 |
Same |
Ademetionine |
D07128 |
- |
- |
[15] 6, 14, 22, 43, 44, 46, 47, 49, 50, 60, 84, 93, 96, 97, 172 |
108 |
Sildenafil |
Sildenafil |
D02229, D08514 |
[1] PDE5A |
[3] Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
[15] 6, 46, 50, 51, 85, 86, 113, 210, 211, 212, 225, 226, 278, 294, 299 |
109 |
Siponimid |
- |
- |
- |
- |
[1] 50 |
110 |
Siponimod |
Siponimod |
D11460 |
[2] S1PR1, S1PR5 |
[3] FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
[2] 13, 50 |
111 |
Sodium thiosulfate |
- |
- |
- |
- |
[1] 50 |
112 |
Solu-medrol inj. pso lqf 40mg |
- |
- |
- |
- |
[1] 50 |
113 |
Steroids |
- |
- |
- |
- |
[7] 46, 50, 51, 63, 66, 96, 97 |
114 |
Tacrolimus |
Tacrolimus |
D00107, D08556 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[29] 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
115 |
Tocilizumab |
Tocilizumab |
D02596 |
[1] IL6R |
[11] Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
116 |
Tofacitinib |
Tofacitinib |
D09970 |
[4] JAK1, JAK2, JAK3, TYK2 |
[34] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
117 |
Ustekinumab |
Ustekinumab |
D09214 |
[3] IL12A, IL12B, IL23A |
[25] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
[15] 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 |
118 |
Ustekinumab 6 mg/kg |
Ustekinumab |
D09214 |
[3] IL12A, IL12B, IL23A |
[25] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
[1] 50 |
119 |
Ustekinumab 90 mg |
Ustekinumab |
D09214 |
[3] IL12A, IL12B, IL23A |
[25] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
[3] 50, 93, 96 |
120 |
Vib7734 |
- |
- |
- |
- |
[4] 49, 50, 51, 53 |
121 |
Vitamin d |
Vitamin d |
- |
- |
- |
[18] 13, 19, 41, 46, 49, 50, 68, 93, 95, 96, 98, 179, 222, 228, 235, 274, 298, 299 |
122 |
Xoma 052 |
- |
- |
- |
- |
[5] 41, 46, 50, 56, 106 |
123 |
Yellow fever vaccine |
Yellow fever vaccine |
D06347 |
- |
- |
[7] 40, 44, 46, 50, 51, 52, 53 |
124 |
Yellow fever vaccine (17d) |
Yellow fever vaccine |
D06347 |
- |
- |
[7] 40, 44, 46, 50, 51, 52, 53 |